As far as the combination of HIPEC and bevacizumab in ovarian cancer, our data are consistent with the recent paper by Gouy et al. which demonstrated that bevacizumab maintenance treatment could be safely completed on around one-third of patients, with six cycles of carboplatin-paclitaxelchemotherapy followed by IDS and HIPEC. Interestingly, this percentage is completely in line with results from the GOG- 0218 and ICON-7 trial, suggesting that even an aggressivemultimodal approach combining neoadjuvant chemotherapy (NACT), IDS and HIPEC does not affect the chance of successfully complete bevacizumab-maintenance therapy without enhanced toxicities